Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Thursday, December 22, 2022
Translocation from the cytoplasm to nucleus and integration of reverse-transcribed SARS-CoV-2 spike mRNA into the genomic DNA of COVID-19 mRNA-vaccinated individuals positive for HIV-1 or other ...
read more
Monday, December 12, 2022
Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized COMIRNATY® Original & Omicron BA.4/BA.5 as a 10-µg booster dose for children 5 through <12 years="" of="" age.="" this="" booster="" is="" approved="" for="" use="" at="" least="" 6="" months="" after="" completing="" the="" primary="" course="" of="" the="" companies'="" original="" covid-19="" vaccine="" (comirnaty).="" years="" of="" age.="" this="" booster="" is="" approved="" for="" use="" at="" least="" 6="" months="" after="" completing="" the="" primary="" course="" of="" the="" companies'="" original="" covid-19="" vaccine="">12>...
read more
Friday, December 09, 2022
Pfizer Inc. and BioNTech SE announced the companies have received Fast Track Designation from the FDA for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help ...
read more
Thursday, December 08, 2022
Novavax announced that Health Canada has approved a supplement to a New Drug Submission (sNDS) for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization...
read more
Friday, December 02, 2022
Hoffmann-La Roche Limited (Roche Canada) has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA ® IV (tocilizumab for injection) for adult patients ...
read more
Thursday, December 01, 2022
Novavax, Inc. announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent ...
read more
Thursday, December 01, 2022
The COVID-19 pandemic posed unprecedented challenges to the U.S. Food and Drug Administration’s (FDA) inspection program. Emergency public health measures, including global travel restrictions and ...
read more
Wednesday, November 23, 2022
Ascletis Pharma Inc. announced that the FDA approved the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID...
read more
Monday, November 21, 2022
Novavax, Inc. announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent ...
read more
Friday, November 18, 2022
Pfizer and BioNTech announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (...
read more
Monday, November 14, 2022
BioNTech announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing to acquire one of its GMP-certified ...
read more
Thursday, November 10, 2022
Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 5/5-µg) is now recommended for marketing authorization ...
read more
Wednesday, November 09, 2022
Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company's BA.1 vaccine candidate (NVX-CoV2515) met the primary ...
read more
Wednesday, November 09, 2022
FDA has issued an emergency use authorization (EUA) for Kineret (anakinra) injection for the treatment of COVID-19 in hospitalized adults with pneumonia requiring supplemental oxygen (low- or high-...
read more
Friday, November 04, 2022
Health Canada has authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron BA.4/BA.5 subvariants. It is authorized for use as a booster dose in individuals 18 ...
read more